Passage Bio, Inc. (PASG)
- Previous Close
1.2200 - Open
1.2450 - Bid 1.2800 x 100
- Ask 1.3400 x 100
- Day's Range
1.2300 - 1.3200 - 52 Week Range
0.5750 - 1.7900 - Volume
75,400 - Avg. Volume
347,504 - Market Cap (intraday)
81.328M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8600 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
www.passagebio.comRecent News: PASG
Performance Overview: PASG
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PASG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PASG
Valuation Measures
Market Cap
81.33M
Enterprise Value
-6.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.73
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.07
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.67%
Return on Equity (ttm)
-65.29%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-102.06M
Diluted EPS (ttm)
-1.8600
Balance Sheet and Cash Flow
Total Cash (mrq)
114.29M
Total Debt/Equity (mrq)
23.63%
Levered Free Cash Flow (ttm)
-48.22M